{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:04:17Z","timestamp":1762481057829,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.gore.2023.101160","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T11:24:59Z","timestamp":1678533899000},"page":"101160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-3576","authenticated-orcid":false,"given":"Hector S.","family":"Porragas-Paseiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saketh","family":"Guntupalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"S2","key":"10.1016\/j.gore.2023.101160_b0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijgo.12610","article-title":"Cancer of the vagina","volume":"143","author":"Adams","year":"2018","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"20","key":"10.1016\/j.gore.2023.101160_b0010","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10265","key":"10.1016\/j.gore.2023.101160_b0015","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.gore.2023.101160_b0020","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.1976.03270110011002","article-title":"Exposure in utero to diethylstilbestrol and related synthetic hormones. Association with vaginal and cervical cancers and other abnormalities","volume":"236","author":"Ervin","year":"1976","journal-title":"JAMA"},{"key":"10.1016\/j.gore.2023.101160_b0070","series-title":"StatPearls","article-title":"Pembrolizumab","author":"Flynn","year":"2023"},{"issue":"2","key":"10.1016\/j.gore.2023.101160_b0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1999.5471","article-title":"Behavior of Estrogen-Associated Female Genital Tract Cancer and Its Relation to Neoplasia Following Intrauterine Exposure to Diethylstilbestrol (DES)","volume":"76","author":"Herbst","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.gore.2023.101160_b0025","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM197104222841604","article-title":"Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women","volume":"284","author":"Herbst","year":"1971","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gore.2023.101160_b0035","doi-asserted-by":"crossref","unstructured":"Herbst, A.L., Scully, R.E., 1970. Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas). Cancer 25(4), 745\u2013757. doi:10.1002\/1097-0142(197004)25:4<745::aid-cncr2820250402>3.0.co;2-2.","DOI":"10.1002\/1097-0142(197004)25:4<745::AID-CNCR2820250402>3.0.CO;2-2"},{"issue":"4","key":"10.1016\/j.gore.2023.101160_b0050","first-page":"1233","article-title":"Difficulties of clinical and histopathological diagnosis in advanced vulvar clear cell carcinoma","volume":"59","author":"Herghelegiu","year":"2018","journal-title":"Rom J. Morphol. Embryol."},{"issue":"3","key":"10.1016\/j.gore.2023.101160_b0055","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ygyno.2017.06.028","article-title":"Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up","volume":"146","author":"Huo","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101160_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2021-002517","article-title":"Updates in the treatment of vaginal cancer","volume":"32","author":"Jhingran","year":"2022","journal-title":"Int. J. Gynecologic Cancer"},{"issue":"5","key":"10.1016\/j.gore.2023.101160_b0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/PAP.0b013e31826663b1","article-title":"Clear Cell Carcinoma of the Female Genital Tract (Not Everything Is as Clear as it Seems)","volume":"19","author":"Offman","year":"2012","journal-title":"Adv. Anat. Pathol."},{"issue":"2","key":"10.1016\/j.gore.2023.101160_b0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2022.01.029","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Shapira-Frommer","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2023.101160_b0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved Survival with Bevacizumab in Advanced Cervical Cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:59:34Z","timestamp":1762480774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":14,"alternative-id":["S2352578923000292"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101160","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101160"}}